Linkedin Twitter Envelope

News

Home
/
/
/
Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©)

The purpose of the assessment is to evaluate Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Final version of the assessment was published in October 2017. Below is the documentation provided by the Joint Assessment authoring team:

Regorafenib_Final Assessment Report
External comments & answers 2nd draft assessment regorafenib_1
Project Plan PTJA02 Regorafenib for HCC (FINAL)_0_1

More news

OUR NETWORK

CAREERS

HELP

eunethta@zinl.nl

CONTACT US

This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.

©2021 EUnetHTA All rights reserved.

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.
Accept and Close